Azole interactions with multidrug therapy in pediatric oncology

被引：13

作者：

Ruggiero, Antonio ^{[1
]}

Arena, Roberta ^{[1
]}

Battista, Andrea ^{[1
]}

Rizzo, Daniela ^{[1
]}

Attina, Giorgio ^{[1
]}

Riccardi, Riccardo ^{[1
]}

机构：

[1] Univ Cattolica Sacro Cuore, Pediat Oncol Div, A Gemelli Hosp, I-00168 Rome, Italy

来源：

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY | 2013年 / 69卷 / 01期

关键词：

Azoles; Drug interactions; Invasive fungal infections; Children; STEADY-STATE PHARMACOKINETICS; 3A4 INHIBITOR ITRACONAZOLE; CYTOCHROME-P450; 3A4; FUNGAL-INFECTIONS; CLINICAL PHARMACOKINETICS; SYSTEMIC ANTIMYCOTICS; PLASMA-CONCENTRATIONS; DRUG-INTERACTIONS; ANTIFUNGAL DRUGS; VORICONAZOLE;

D O I：

10.1007/s00228-012-1310-x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Patients with cancer receive multidrug therapy. Antineoplastic agents and supportive care drugs are often administered together, leading to potential drug-drug interactions. These interactions may have significant clinical implications in terms of toxicity or a decrease in the efficacy of the treatment administered. Here, we focus on the role of azoles and their main pharmacokinetic interactions with the principal classes of drugs used in pediatric oncology. The co-administration of azoles and antineoplastic agents, corticosteroids, immunosuppressants, antacids, antiemetics, antiepileptic drugs and analgesics was investigated, and a practical guide on the management of these drugs when administered together is provided.

引用

页码：1 / 10

页数：10

共 75 条

[1] The effect of the antimycotic itraconazole on the pharmacokinetics and pharmacodynamics of diazepam [J].

Ahonen, J ;

Olkkola, KT ;

Neuvonen, PJ .

FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1996, 10 (03) :314-318

[2] IDENTIFICATION OF HUMAN LIVER CYTOCHROME-P450 ISOFORMS MEDIATING OMEPRAZOLE METABOLISM [J].

ANDERSSON, T ;

MINERS, JO ;

VERONESE, ME ;

TASSANEEYAKUL, W ;

MEYER, UA ;

BIRKETT, DJ .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 36 (06) :521-530

[3] The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin [J].

Backman, JT ;

Kivistö, KT ;

Olkkola, KT ;

Neuvonen, PJ .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (01) :53-58

[4] GEOGRAPHICAL INTERRACIAL DIFFERENCES IN POLYMORPHIC DRUG OXIDATION - CURRENT STATE OF KNOWLEDGE OF CYTOCHROMES P450 (CYP) 2D6 AND 2C19 [J].

BERTILSSON, L .

CLINICAL PHARMACOKINETICS, 1995, 29 (03) :192-209

[5]

Billaud EM, 1998, BRIT J CLIN PHARMACO, V46, P271

[6] Drug-drug interactions in oncology: Why are they important and can they be minimized? [J].

Blower, P ;

de Wit, R ;

Goodin, S ;

Aapro, M .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2005, 55 (02) :117-142

[7] EFFECT OF FLUCONAZOLE ON THE DISPOSITION OF PHENYTOIN [J].

BLUM, RA ;

WILTON, JH ;

HILLIGOSS, DM ;

GARDNER, MJ ;

HENRY, EB ;

HARRISON, NJ ;

SCHENTAG, JJ .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 49 (04) :420-425

[8] Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin [J].

Bottiger, Y ;

Tybring, G ;

Gotharson, E ;

Bertilsson, L .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 62 (04) :384-391

[9] Clinical Relevance of the Pharmacokinetic Interactions of Azole Antifungal Drugs with Other Coadministered Agents [J].

Bruggemann, Roger J. M. ;

Alffenaar, Jan-Willem C. ;

Blijlevens, Nicole M. A. ;

Billaud, Eliane M. ;

Kosterink, Jos G. W. ;

Verweij, Paul E. ;

Burger, David M. .

CLINICAL INFECTIOUS DISEASES, 2009, 48 (10) :1441-1458

[10]

Buggia I, 1996, ANTICANCER RES, V16, P2083

← 1 2 3 4 5 6 7 8 →